Ensysce Biosciences Statistics
Share Statistics
Ensysce Biosciences has 1.64M
shares outstanding. The number of shares has increased by 176.49%
in one year.
| Shares Outstanding | 1.64M |
| Shares Change (YoY) | 176.49% |
| Shares Change (QoQ) | 7.68% |
| Owned by Institutions (%) | 0% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 90 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 134.94K, so 8.2% of the outstanding
shares have been sold short.
| Short Interest | 134.94K |
| Short % of Shares Out | 8.2% |
| Short % of Float | 8.34% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
| PE Ratio | 0 |
| Forward PE | 0.07 |
| PS Ratio | 0 |
| Forward PS | 0.1 |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Ensysce Biosciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.42,
with a Debt / Equity ratio of 0.08.
| Current Ratio | 2.42 |
| Quick Ratio | 2.42 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | -0.04 |
| Debt / FCF | -0.04 |
| Interest Coverage | 5.22 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,141,032,142,857.14 |
| Employee Count | 7 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -65.81% in the
last 52 weeks. The beta is 1.07, so Ensysce Biosciences's
price volatility has been higher than the market average.
| Beta | 1.07 |
| 52-Week Price Change | -65.81% |
| 50-Day Moving Average | 3.51 |
| 200-Day Moving Average | 5.8 |
| Relative Strength Index (RSI) | 51.17 |
| Average Volume (20 Days) | 1,638,739 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -6,730.1B |
| Net Income | -7,987.2B |
| EBITDA | -6,730.1B |
| EBIT | -9,277.7B |
| Earnings Per Share (EPS) | -4573049.94 |
Full Income StatementBalance Sheet
The company has 3.5M in cash and 301.66B in
debt, giving a net cash position of -301.66B.
| Cash & Cash Equivalents | 3.5M |
| Total Debt | 301.66B |
| Net Cash | -301.66B |
| Retained Earnings | -129,544.3B |
| Total Assets | 5.6M |
| Working Capital | 3.14M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -7,502.7B
and capital expenditures 0, giving a free cash flow of -7,502.7B.
| Operating Cash Flow | -7,502.7B |
| Capital Expenditures | n/a |
| Free Cash Flow | -7,502.7B |
| FCF Per Share | -4295637.32 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
